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Abstract 15 
Cancer genome sequencing has revealed that somatic mutation rates vary substantially across 16 
the human genome and at scales from megabase-sized domains to individual nucleotides.  17 
Here we review recent work that has both revealed the major mutation biases that operate 18 
across the genome and the molecular mechanisms that cause them. The default mutation rate 19 
landscape in mammalian genomes results in active genes having low mutation rates because of 20 
a combination of factors that increase DNA repair: early DNA replication, transcription, active 21 
chromatin modifications and accessible chromatin. Therefore, either an increase in the global 22 
mutation rate or a redistribution of mutations from inactive to active DNA can increase the rate 23 
at which consequential mutations are acquired in active genes. Several environmental 24 
carcinogens and intrinsic mechanisms operating in tumor cells likely cause cancer by this 25 
second mechanism: by specifically increasing the mutation rate in active regions of the genome. 26 
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Introduction  38 
 39 
The large-scale sequencing of tumors and healthy somatic cells presents a unique opportunity 40 
to learn about somatic mutation processes and how mutation rates vary across the human 41 
genome. The primary motivation for tumor genome sequencing was to identify the ‘driver’ 42 
mutations that cause cancer.  Driver mutations are selected for because they promote the 43 
expansion or survival of tumor clones.  However, most somatic mutations in cancer genomes 44 
are inconsequential ‘passenger’ mutations that are under very weak or no selection and 45 
statistical analyses of these passenger mutations have provided many fundamental insights into 46 
the mutation processes that operate in human cells and how these processes vary across the 47 
genome, cell types and individuals. 48 
 49 
Absolute mutation rates are difficult to determine for tumor cells, primarily because the number 50 
of cell divisions that a tumor cell has undergone is hard to establish. However, it has long been 51 
appreciated that many tumors have have an elevated mutation rate, for example because of 52 
inactivated DNA repair pathways [1–3]. In this review, we will not focus on the general 53 
acceleration in mutation rates in a cancer cell. Instead, this text focuses on relative mutation 54 
rates, which are more straightforward to quantify from regional densities of mutations in the 55 
genome. We provide an overview of the patterns of mutations that are observed across regions 56 
of the human genome and our current understanding about their mechanistic underpinnings 57 
when this is known (although often a detailed mechanistic understanding is still lacking). We 58 
place an emphasis on the insight and the novel hypotheses that cancer genomes have yielded 59 
about the organization of mutation processes in human cells.  Our primary focus is on single 60 
nucleotide substitutions and short insertions and deletions. The reasons for this are pragmatic: 61 
structural variation is much more challenging to precisely infer using short-read sequencing and 62 
although progress is being made in both identifying and understanding structural variation, the 63 
influences on its regional rates in the soma are far less well understood [4].  64 
 65 
Variability in mutation rates across the genome may result from two broad causes: differential 66 
accrual of DNA damage and also base mispairing during DNA replication (variation in mutation 67 
supply) or differential repair of damage and mispairs (variation in DNA repair). These influences 68 
are, of course, not mutually exclusive. Recent work has suggested, however, that the latter – 69 
differential DNA repair – appears to play a quantitatively more important role in shaping the 70 
mutation landscape in the human soma. This is consistent with the expectation that mutation 71 




rates are more sensitive to changes in repair rates than to changes in damage rates because 72 
the vast majority of instances of damage are repaired [5].  73 
 74 
Somatic mutation rates vary at multiple resolutions 75 
 76 
As we discuss below, mutation rates in the human genome vary at multiple different scales from 77 
single nucleotides to megabase-sized domains. Importantly, the mechanisms underlying 78 
variation at these different genomic resolutions may be quite different and this often confounds 79 
statistical analyses performed at a certain resolution. For instance, at the resolution of a single-80 
nucleotide, mutation rates are highly dependant on the 5’ and 3’ neighboring nucleotides.  For 81 
example, in the human genome, the spontaneous deamination of methylated cytosine to 82 
thymine results in a substantially increased mutation rate at CG dinucleotides, the majority of 83 
which are methylated in the genome [6,7]. At the other extreme, when examining roughly 84 
megabase-sized chromosomal domains, a major determinant of mutation rates is DNA 85 
replication timing. In this specific case, this is not due to differential damage accumulation, but 86 
due to differential activity of DNA repair, which is preferentially active in early-replicating, gene-87 
rich domains [8]. We will discuss these and other known determinants of regional mutation rates 88 
at length below. 89 
 90 
Genome-wide statistical analyses of the patterns in mutation rate heterogeneity have revealed 91 
mechanisms that marshall DNA repair preferentially towards particular regions of the genome. 92 
Given that the cell’s ability to repair DNA is a limited resource, it is not unexpected that different 93 
repair capacities would be prioritized to different regions, for example those containing genes 94 
essential for cell viability. This differential DNA repair controls the mutation supply to oncogenes 95 
and tumor suppressor genes and may therefore modulate the risk of cancer. Potentially, the 96 
mutation supply to important genes in somatic cells could more broadly affect aging-related 97 
diseases, such as neurodegeneration [9]. With respect to germline mutations, variation in 98 
mutation rates along the chromosomes determines the propensity for obtaining particular 99 
deleterious mutations, and also shapes the genetic diversity of populations. Learning about 100 
patterns of regional mutation rates also has important practical applications. One common use 101 
concerns statistical tests for selection in genomic sequences; such tests are highly dependant 102 
on establishing an accurate baseline for local mutational rates, and any deviations therefrom are 103 
then considered as evidence for either positive selection (in cancer, suggesting oncogenic 104 
mutations) or negative selection (suggesting genes essential to somatic cells). 105 





In between the two extremes mentioned above – the trinucleotide scale and the megabase 107 
domain scale – there is a continuum of resolutions of mutation rate variability which have been 108 
less systematically explored. However there is knowledge that rates of certain mutational 109 
processes vary depending, for instance, on the binding of certain proteins (most prominently, 110 
the sites where the CTCF protein is co-bound with cohesin [10–12]) or on the presence of 111 
certain post-translational histone modifications on nucleosomes – a salient example is the 112 
H3K36me3 mark associated with transcription elongation that can recruit DNA repair proteins 113 
[13–15]. Interactions exist between the mutation patterns at different resolutions, which helps 114 
link mutation patterns to mechanisms. For example, the CTCF-bound motifs were found to be 115 
more mutable, in relative terms, in the same tumors which have a higher proportion of A>C 116 
changes, which allows these two processes to be tentatively linked to the same underlying 117 
mechanism, suggested to be oxidation of the free nucleotide pool [11,16]. Such associations 118 
may help narrow down a list of putative mechanisms and thus to prioritize experimental work. 119 
 120 
In summary, what is known is that regional mutation rates in somatic cells appear highly 121 
variable at different, overlapping scales. What is currently less well explored is how much 122 
systematic variability there exists at each resolution (while rigorously deconvoluting the 123 
variability that overlaps and being able to distinguish it from random noise), how such variability 124 
at every resolution changes between cell types and between individuals, and how much of the 125 
variability is due to differential DNA repair and how much is due to differential damage. More 126 
fundamentally, the identity of the repair and/or damage mechanisms that cause the observed 127 
patterns are still often unknown. 128 
 129 
Features and mechanisms associated with mutation rate variation  130 
 131 
In the following sections we provide an overview of genomic and epigenomic variables known to 132 
be statistically associated with mutation rates at various resolutions.  We also highlight 133 
examples where the underlying molecular mechanisms are known or suspected. 134 
 135 
Variability at the domain scale (105 bp - 106 bp).  The extent of variability in somatic mutation 136 
rates at the scale of roughly megabase-sized domains was appreciated early on, after the 137 
sequencing of the first cancer genomes [17–19].  High mutation rates are strongly correlated 138 
with a high density of repressive chromatin marks (such as the heterochromatin mark 139 




H3K9me3), later replication timing, lower accessibility of DNA as estimated via the density of 140 
DNAse hypersensitive sites (DHS) in the domain, and a lower density of active chromatin marks 141 
(e.g. H3K4me1/2/3). However, correlation does not imply causation and indeed for several of 142 
these variables there is mounting evidence they are likely not causal to mutation rates, or at 143 
least not to a major degree.  Based on statistical analyses that rigorously control for 144 
confounding variables, replication timing (RT) is a feature that is very robustly related with 145 
mutation rates  [15,19–21]. Consistently, changes in RT across cell types correlate well with 146 
changes in mutation rates [8]. The key test of the hypothesis would, however, be an experiment 147 
that changes RT in a controlled manner whilst measuring the impact on additional features such 148 
as chromatin modifications, and this has not yet been performed.  149 
 150 
The converse example of a mutation rate determinant, often cited as associated in the literature, 151 
is chromatin accessibility (usually measured by the density of the DHS), which is associated 152 
with locally lower mutation rates [22]. However, meticulous statistical analyses suggest that 153 
DNA accessibility is less likely to be causal for many types of mutational processes, or at least 154 
the processes commonly generating a high number of mutations [15]. An informal interpretation 155 
of these analyses is that the large, usually several-fold difference in mutation rates between 156 
chromosomal domains cannot be explained by the cumulative effect of smaller differences in 157 
mutation rates between accessible sites (DHS) and their local neighborhoods in DNA. In other 158 
words, the density of DHS sites at the megabase scale, strongly correlated with mutation rates, 159 
likely reflects a different mechanistic cause because at the local scale DHS have a more subtle 160 
effect on mutability. (In fact, the density of DHS site was found to be an accurate predictor of RT 161 
[23], thus explaining the confounding.)  Similar reasoning would hold for the strong correlation of 162 
the domain-scale density of the enhancer/promoter chromatin marks (H3K4 methylation) [24], 163 
which however at the local scale show little association with mutability. They are therefore 164 
unlikely to be causal of the domain-scale variation in mutation rates. 165 
 166 
There is mounting evidence for a mechanism underlying the striking domain-scale variability in 167 
mutation rates: differential activity of DNA mismatch repair (MMR), which preferentially prevents 168 
mutations in early-replicating, euchromatic regions. This was first discovered because MMR-169 
deficient tumors of various organs display a severe loss of domain-scale variability, exhibiting a 170 
‘flat’ landscape [8], a finding later confirmed by direct experiments [25,26]. Further evidence 171 
came from analysis of trinucleotide mutation spectra: those 5’ and 3’ contexts which become 172 
more mutable upon MMR failure are the same contexts that become less depleted in early-173 




replicating DNA [8,27,28]. The importance of MMR for domain-scale mutation rate variability has 174 
also been confirmed by direct experiments where MMR activity was abolished in human cell 175 
lines [25,26] resulting in a ‘flat’ distribution of mutations across the genome.  Similar results 176 
have also been reported for MMR in yeast [5,29] and in Arabidopsis [30]. Additionally, 177 
nucleotide excision repair (NER) appears to be less active in late-replicating heterochromatin, 178 
because the mutation rate differential is diminished in skin cancers of germline NER-deficient 179 
patients [31]. Differential DNA repair therefore seems to be a major reason that mutability 180 
landscapes exist, both in the human genome and in the other eukaryotes.  181 
 182 
There are several open questions related to this domain-scale mutation rate variation. First, 183 
does MMR decrease in accuracy, or in efficiency, or both in late-replicating DNA and what is the 184 
mechanism causing this? Plausible mechanisms could be the preferential loading of MMR 185 
complexes onto early replicating euchromatin [13], depletion or modification of a repair factor 186 
late in S-phase, the reduced accessibility of heterochromatin to repair factors, or simply the 187 
reduced time available for the repair of late replicating DNA [32,33].  The second open question 188 
concerns the mechanism by which MMR reduces various mutation types. Mismatch errors in 189 
DNA replication are a natural substrate for MMR and likely to be one of the most abundant 190 
mutation types. However certain types of mutations that are associated, for examples, with 191 
bulky nucleotide adducts or UV-related DNA damage, also appear to have similar domain-scale 192 
distribution in mutation rates in tumor genomes and it is not clear how MMR contributes to their 193 
repair.  One possible explanation is that MMR proteins can serve as sensors for damage, 194 
binding to a lesion to promote recruitment of other repair pathways [34,35]. Further analyses 195 
and experimental work are needed to address these questions. 196 
 197 
 198 








Variability at the gene scale (103 bp - 105 bp). Cancer genomics has provided ample evidence 203 
that mutation rates differ between different genes in a manner independent of differences 204 
between chromosomal domains. Several types of statistical associations were reported, 205 
sometimes with suggestive evidence for mechanisms. The effect size of such between-gene 206 
differences in mutation rates is usually more modest than the striking, several-fold differences 207 
between chromosomal domains. Nonetheless such mutation rate gradients at the genes 208 
(meaning: between genes, and, in some instances, across the parts within the gene body) are 209 
of interest because they are informative about mechanisms of mutagenesis and DNA repair. An 210 
additional interest lies in the fact that mutagenesis within genes -- particularly coding regions, 211 
UTRs, and promoters -- is more likely to have downstream functional consequences for cancer, 212 
aging and other diseases. 213 
 214 
The most striking trend in mutation patterns observed at the gene-scale is transcription-related 215 
and affects the entire gene body: the asymmetry in mutation rates between the transcribed and 216 
the non-transcribed DNA strands. This is evident only for some mutational processes, falling 217 
into two groups: a strand bias resulting from DNA damage that can be seen by the transcription-218 
coupled nucleotide excision repair (NER) pathway where the strand bias results from differential 219 
NER [36–38] and a strand bias resulting from transcription-coupled damage, which is 220 
mechanistically currently mysterious and was reported in liver tumors [39] and in healthy 221 
neurons [40]. Most mutational processes (as defined by the trinucleotide mutation signatures) 222 
do not exhibit a transcriptional strand bias [36,39].  223 
 224 
In addition, higher transcription levels are generally associated with reduced mutation rates in 225 
both strands of genes [37,38], although it is not clear to which extent this is due to the 226 
correlation of expression levels with other genomic features, such as the abundance of higher-227 
expressed genes in early replication time regions. Some very specific cases of mutational 228 
processes may also have elevated rates in highly transcribed regions but without clear evidence 229 
of a mutational strand bias, for instance transcription-associated mutagenesis due to oxidative 230 
damage was reported in a human cell line [34] and highly expressed lineage-specific genes in 231 
several tumor types harbored many indel mutations [41]. 232 





One widespread mechanism by which highly expressed genes have a reduced mutation rate is 234 
revealed by the association between a particular histone modification – H3K36me3 – and 235 
increased DNA repair efficiency.  H3K36me3 is a mark associated with transcription elongation, 236 
deposited by a histone methyltransferase recruited by the elongating form of the RNA 237 
polymerase II. H3K36me3 can recruit the MSH6 protein of the MMR pathway [13] and in a 238 
large-scale analysis of cancer genomes the high levels of the H3K36me3 mark were found to 239 
have a strong association with up to two-fold lower mutation rates, after rigorously controlling for 240 
other confounding variables such as DNA accessibility and replication time, thus suggesting a 241 
causal role of H3K36me3 [15]. This association disappears in MMR-deficient cancers, providing 242 
evidence that MMR recruitment causes lower mutation rates at H3K36me3-marked regions [15], 243 
which predominantly occur in bodies of highly transcribed genes and increase from the 5’ 244 
towards the 3’ gene end [42,43]. Experimental work in a cell line model provides strong support 245 
for the causal role of H3K36me3 in protection from mutations via marshalling MMR activity 246 
towards expressed genes [34]. Of note, the H3K36me3 mark has also been proposed to recruit 247 
another type of DNA repair – homologous recombination [14]. 248 
 249 
Within some genes, exons may accumulate slightly higher levels of H3K36me3 than introns, 250 
which is consistent with modestly reduced mutation rates in exons observed in cancer 251 
[22,34,44], which might thus result from differential repair. However this observation is 252 
confounded by technical issues: the repeat content and G+C content differences between 253 
exons and introns may affect DNA sequencing, short read alignment and mutation calling; upon 254 
stringent filtering of mutations and control for confounding mutational processes, there were no 255 
observable differences in mutability between exons and introns [45]. Additionally, negative 256 
selection against exonic splicing elements has been suggested to reduce exonic mutation 257 
density [46]. A further observation involves an apparent depletion of oxidative DNA damage in 258 
exons compared to introns [47]. These associations and proposed mechanisms are not 259 
necessarily mutually exclusive and need to be resolved. The modest effect size complicates 260 
statistical analyses to deconvolute these factors. 261 
 262 
In addition to the mechanisms above, which for the most part invoke differential DNA repair to 263 
explain lower mutation rates in active chromatin, there is experimental evidence that differential 264 
DNA damage might, at least in part, underlie lower mutation rates in active regions. For 265 
instance, genome-wide maps of UV damage suggest that this type of insult affects inactive, 266 




heterochromatic regions more strongly [48], potentially because of the peripheral placement of 267 
heterochromatin in the nucleus. In a similar vein, genic regions were reported to have a lower 268 
rate of oxidative damage compared to intergenic regions [47]. Broadly, this distribution of 269 
damage does indeed mirror the distribution of mutations observed in somatic cells undergoing 270 
UV or oxidative-stress related mutagenesis [47,48]. Further experimental work that combines 271 
both differential damage mapping and mutation rate heterogeneity data in a rigorous joint 272 
analysis is warranted to quantitate the contributions of differential damage versus differential 273 
repair to individual mutational processes. 274 
 275 
Variability at the sub-gene scale (101 bp-103 bp). Various genomic regions considerably smaller 276 
than the size of genes have also been associated with certain types of mutational processes in 277 
certain cell types: mutational processes operating at this scale tend to have higher tissue- and 278 
mutagen-specificity than processes at larger scales. This is perhaps unsurprising, given that 279 
such processes (at least the ones described thus far) often result from binding of a particular 280 
protein to a certain site in DNA, rather than a global property of the genome maintenance 281 
machinery.  282 
 283 
A salient example of such phenomena is the high mutation rate at the binding sites of the CTCF 284 
protein, a regulator of transcription and of chromatin architecture. CTCF sites were found to be 285 
highly mutable in colon cancer, stomach cancer, liver cancer and melanoma  [10–12,49], where 286 
hypermutation is conditional on the concomitant binding of cohesin, a partner protein, to the site. 287 
There is suggestive data that this may be due to exclusion of DNA repair processes from the 288 
CTCF sites, including both MMR and NER [11,12]. The exact sites in (or adjacent to) the CTCF 289 
motif that are hypermutable, intriguingly, differ between the mutagenic exposures: UV 290 
mutagenesis is associated with G>A/C>T changes at one set of sites in the motif [12], while 291 
mutagenesis due to ‘Signature 17’ (putatively, oxidative damage to the guanine in the free 292 
nucleotide pool [16]) is associated with A>C/T>G mutations at a different set of sites [11]. 293 
Overall, therefore, both differential DNA damage and differential repair are likely to play a role in 294 
CTCF site hypermutability. An open question is certainly whether such mutations, which likely 295 
disrupt CTCF binding, have functional consequences that might be expected given important 296 
roles of CTCF as an architectural protein and ‘insulator’ for chromatin states. 297 
 298 
In addition to CTCF sites, the binding sites for the ETS family of transcription factors (TFs) also 299 
register very high mutation rates. However, unlike CTCF sites, this effect is observed in skin 300 




cancers but not in other cancer types [50,51]. Also in contrast to CTCF sites, differential DNA 301 
repair does not appear to play a role in the increased mutation rates at ETS sites. Instead, it 302 
was proposed that the binding of ETS TFs increases the propensity of DNA to be damaged by 303 
UV radiation [50,51]. Beyond the strong effect of bound CTCF and the ETS-family TFs, there is 304 
also a more modest but general effect of TF binding (not particular to any specific TF) that 305 
increases mutation rates by a different mechanism -- by interfering with NER activity [52,53]. 306 
This is observable in skin cancer and in other cancers exposed to mutagens that can be 307 
countered by NER, such as lung cancers, but is absent in other common cancers such as colon 308 
or breast. One intriguing observation is that mutation rates tend to be more strongly increased at 309 
TF sites in promoters than at the same TF sites in enhancers [52]. This might hint at different 310 
manner of TF binding between promoter and enhancers, or, alternatively, may suggest that TF 311 
binding is statistically associated with mutability but not itself causal, with another factor at 312 
promoters being the cause of the local deficiency in NER. Caution must be exercised in 313 
interpreting the effects of individual TFs on mutation rates because various TFs often bind in 314 
clusters and the clusters are also often marked by CTCF/cohesin binding [54]. Deconvoluting 315 
the effect of a particular TF from the neighboring binding of CTCF and other factors is critical for 316 
measuring the effect size of individual contributors. 317 
 318 
In addition to the binding of CTCF and certain transcription factors, nucleosome occupancy has 319 
long been associated with altered patterns of genetic variation in populations and across 320 
species [55–59]. Consistent with this, nucleosome occupancy was shown to associate with 321 
subtle local changes in somatic mutation rates, evident in a periodic pattern corresponding to 322 
the internucleosomal distance of approximately 200 nt and additionally an approximately 10nt 323 
periodicity corresponding to the rotational constraints of DNA wrapped around nucleosomes  324 
[60–63]. Several lines of evidence suggest that this is due to differential DNA repair (there is 325 
evidence for MMR, NER and possibly BER playing a role): the pattern appears dependant upon 326 
functional repair pathways and it is evident in mutational signatures associated with repair 327 
deficiencies. Additionally, there is evidence that some types of DNA damage, in particular 328 
cytosine deamination and UV-catalyzed pyrimidine dimer formation, is modulated by 329 
nucleosome binding [55,60].  330 
 331 
 332 





Figure 2. Associations of regional mutation rates with genomic and epigenomic variables, 334 
sorted by approximate size of affected region (x axis) and magnitude of enrichment/depletion (y 335 
axis). 336 
 337 
Variability at the motif scale (1 - 101 bp). At the smallest scale, mutation rate at individual 338 
nucleotides can depend strongly on their immediate 5’ and 3’ neighbors, with these 339 
dependencies suggesting the mutational process that generated the mutation. For example, a 340 
C>T change in a TCW context (where W=A or T) commonly results from the activity of an 341 
enzyme from the APOBEC family of cytosine deaminases [64,65]. However the same C>T 342 
change but in an NCG context is commonly due to spontaneous cytosine deamination at 343 
methylated cytosines [6,7], while cytosines bearing the 5-hydroxymethyl modification were 344 
associated with more C>G changes but less C>T changes [7,66]. The relative abundance of 345 
mutations in different contexts informs about which mutagenic processes are ongoing in that 346 
individual. Conversely, analyzing how the mutability of trinucleotides changes across individuals 347 
identifies ‘mutational signatures’, mathematical constructs that aim to represent individual 348 
mutagenic mechanisms.  More than 50 such signatures were found thus far, where mechanisms 349 
are known or proposed for some, and are quite varied, involving failures in DNA repair, 350 
exposure to mutagenic agents (exogenous or endogenous), and to spontaneous DNA damage 351 




[36,61,67]. The mechanisms are, however, still unknown for many of these signatures or are 352 
speculative at best. It is also in many cases unclear that there is a one-to-one mapping of any 353 
particular signature to a mutagenic process, given that slightly different computational methods 354 
result in quite different sets of signatures. These issues are expected to lessen as the statistical 355 
methodologies mature. 356 
 357 
Several extensions of the above mutational signatures framework are promising, in terms of 358 
better deconvoluting mutational processes from genomic data, and also in terms of helping 359 
interpret the processes and assigning them to a possible mechanism. Longer motifs including 360 
pentanucleotides and heptanucleotides have been examined for differential mutability in the 361 
soma and germline, establishing that these extended oligonucleotide contexts indeed matter for 362 
mutability in human for certain types of mutational processes [68–70].  However, for analysis of 363 
motifs longer than trinucleotides, the amount of data becomes limiting; methods have been 364 
proposed to ameliorate this [71]. Additionally, repetitive DNA motifs with propensity to form 365 
certain DNA structures were found to be associated with certain types of mutations [72,73], 366 
suggesting that DNA structure might be causal to mutagenesis. The difficulty of calling 367 
mutations at repetitive DNA from short-read sequencing are a challenge for such analyses.  In 368 
addition to the most common mutation type -- single nucleotide substitutions -- mutational 369 
signatures were recently proposed for short insertions and deletions [74], for structural variants 370 
[75,76] and for clustered mutations [15]. Certain mutagenic mechanisms may be predominant in 371 
one type of mutational signature, for instance mutagenic activity due to use of error-prone DNA 372 
polymerase eta appears widespread and detectable via patterns of clustered mutations [15,77]. 373 
In other instances, the same process is evident across different types of mutational signatures. 374 
For instance, MMR deficiencies result in a mutation spectrum rich in e.g. GCN>GTN changes 375 
(among others) and additionally they result in an increased burden of indels, typically with a bias 376 
towards short deletions. Similarly, deficiency in the homologous recombination pathway results 377 
in both single-nucleotide changes of a certain spectrum [36,78], in short deletions with 378 
microhomology at borders, and in a pattern of copy-number changes [75,79] .  379 
 380 
The redistribution of mutations in cancer 381 
It is well expected that exposures to DNA damaging agents and failing DNA repair increase 382 
overall mutation rates. However genome sequencing of cancers has also provided evidence of 383 
another, less appreciated, but similarly widespread phenomenon: that exposure to mutagens 384 
and DNA repair failures also cause changes in the relative mutation rates of chromosomal 385 




regions. Such ‘redistribution’ of mutations across the genome due to mutagenic exposures is 386 
likely to have important functional consequences when it occurs, in particular it may often 387 
increase the burden of mutations specifically in the regions where mutations have higher 388 
impact. This is because the default mutation rate landscape in mammalian genomes implies 389 
that active genes are protected via a combination of factors that preferentially recruit DNA 390 
repair: early DNA replication, transcription, chromatin accessibility, and the H3K36me3 391 
chromatin mark. This protection of active chromatin by focused DNA repair is known to be lost 392 
in some mutator phenotypes and upon exposure to carcinogens, as we outline below. 393 
 394 
Very prominently, human and other eukaryotic cells that lose MMR activity also lose the 395 
protection of early-replicating domains against mutation [8]. Not only does MMR loss imply an 396 
overall increase in mutation rates, but the increase is proportionally much larger at early-397 
replicating, euchromatic, gene-rich domains. This is in contrast to another type of mutator 398 
phenotype due to mutations in the proofreading domain of DNA polymerase epsilon: these 399 
cancers usually have an even higher mutation burden than MMR-deficient cancers however 400 
they retain protection of early-replicating domains [8].  401 
 402 
In addition to global MMR failure, other types of DNA repair alterations were linked with 403 
mutation redistribution. For instance, bladder cancers with mutations in the ERCC2 gene, 404 
encoding a helicase that participates in the NER pathway, show an altered mutation 405 
trinucleotide spectrum [80,81] but also show a loss of mutation protection in active chromatin.  406 
 407 
Another, more widespread instance of mutation redistribution in many cancer types was recently 408 
proposed to occur via activity of error-prone, non-canonical MMR pathway [15]. This pathway is 409 
known to use the TLS DNA polymerase eta (a product of the POLH gene, also called XPV) 410 
during MMR [82,83], and the mutational pattern of clustered mutations at A:T nucleotide pairs 411 
observed in many tumors is consistent with activity of POLH [77]. Of note, while clustered 412 
mutations are rather rare, it is likely that POLH also creates a large number of (unclustered) 413 
single-nucleotide changes, which are directed towards H3K36me3-marked active genes, 414 
including cancer driver genes [15]. In multiple cancer types, this clustered mutational pattern is 415 
associated with exposure to various carcinogens, such as UV light, tobacco smoke and 416 
oxidative damage [15]; this is again consistent with the experimental observation that various 417 
mutagenic insults can recruit POLH to chromatin [82,83]. Interestingly, the mutational patterns 418 
of POLH were associated with alcohol consumption in multiple cancer types, providing a 419 




possible mechanism by which alcohol is carcinogenic: rather than increasing the global mutation 420 
rate, alcohol or its metabolites increase the local mutation rate in active genes by triggering 421 
error-prone DNA synthesis [15]. Consistent with this, multiple other studies have reported an 422 
enrichment of mutations at A:T nucleotide pairs in esophageal and liver cancers of alcohol 423 
consumers [84,85] . 424 
 425 
However, redistribution of mutations also happens not only due to inactivity (or non-canonical 426 
activity) of DNA repair pathways, but also because of exposure to certain DNA damaging 427 
agents. A salient examples of this is an endogenous mutagen -- the APOBEC family of cytosine 428 
deaminases, where the APOBEC3A and APOBEC3B paralogs are thought to cause mutations 429 
in cancer [64,86,87]. In contrast to most other mutation types, mutations due to APOBEC 430 
activity are enriched in early-replicating, gene-rich regions [88,89] and, consistently, have a high 431 
potential for generating impactful mutations in cancer driver genes [90,91].  432 
 433 
Additional examples of mutations that are directed towards active genes have a less clear 434 
mechanistic basis but nonetheless may have a substantial mutagenic footprint (in all cases, 435 
shown for a rather restricted range of cell types): transcription-associated mutagenesis, with a 436 
strong DNA strand bias, reported in liver cancers [39], a modest increase in mutation burden at 437 
transcribed genes in healthy neurons [40], and a high burden of small indels in very highly 438 
expressed lineage-specific genes in lung, liver, thyroid and stomach tumors [41]. Finally, one 439 
mutagen that is known to target active, highly expressed regions (mostly gene promoters and 440 
downstream regions) is AID [92], a cytosine deaminase which acts in B-lymphocytes in a 441 
physiological (not pathological) process that serves to diversify antibody genes. It has been 442 
reported that AID can be ectopically expressed and cause mutations in non-lymphoid tissues 443 
[93–95]; indeed, many cancers of various types exhibit a clustered mutational signature 444 
apparently consistent with AID, which is also broadly targeted to active regions [15]. AID 445 
mutagenesis is a known cause of lymphoid cancers, and the current data, while only 446 
suggestive, merits further research to investigate a potential role in mutagenizing diverse non-447 
blood tissues by AID or an AID-like activity, with potential for causing cancer therein. 448 
 449 
 450 






Figure 3. Redistribution of relative mutation rates towards active chromatin by failures of DNA 453 
repair and by exposure to mutagens. TAM, transcription-associated mutagenesis. MMR, DNA 454 
mismatch repair. 455 
 456 
 457 
Outlook: challenges in genomic studies of mutation patterns.   458 
 459 
Statistical analyses of mutation distributions across the genomes of somatic cells – including not 460 
only tumors but also healthy cells [96,97] and cell lines [26,98,99] – have provided valuable 461 
insights into the mechanisms that underlie mutation rate variation. The approaches that have 462 
been used can, however, likely still be improved to provide deeper insights into mechanisms of 463 
DNA repair and mutagenesis.   464 
 465 
First, of course, there is a need for more data.  A larger number of whole genome sequences 466 
will afford more statistical power to examine mutation rate variability at finer resolutions.  467 
 468 
Second, there is a need to further develop and refine specialized statistical methods for 469 
discovering associations between mutation distributions and various genomic features, while 470 
controlling for both the strong confounding correlations that exist between many (epi)genomic 471 
features (such as chromatin accessibility, replication timing and transcription) and the 472 
heterogeneity of mutational processes across tumors (e.g. early replicating regions are G+C 473 
rich thus a process that mutates only C:G pairs creates an artefactual enrichment in early 474 




replicating DNA). We have applied one statistical methodology to this problem [15,20] but it is 475 
likely that further developments and additional approaches will be required to fully address 476 
these issues. Adjusting for the known confounders increases the confidence that the discovered 477 
associations may be causal and thus inform about the mechanism behind the generation of (or 478 
protection from) mutations in certain regions.  479 
 480 
However, in observational studies, no matter how carefully conducted, causality cannot be 481 
inferred with full certainty. Therefore, a third direction for research which is complementary to 482 
the analysis of cancer genomes is to perform controlled experiments, generating mutations by 483 
perturbing DNA repair pathways or chromatin modification pathways or by exposure to specific 484 
mutagens, and then observing the genome-wide patterns that emerge. This type of work has 485 
been recently initiated in multiple model systems including mice [20,100,101], mammalian and 486 
chicken cell lines [26,98,99,102], C. elegans [103,104], and yeast [5].  The genome-wide 487 
patterns observed in animal/cell-line models can then be matched to those observed in human 488 
samples, thus assigning a mechanistic basis for the mutational biases. This was performed 489 
mainly for trinucleotide mutation spectra but other kinds of patterns can, in principle, be 490 
examined in the same way.  491 
 492 
The challenges in interpreting genome-wide studies of mutation rates highlighted above mean 493 
that it is often necessary to be cautious when interpreting the results of correlation-based 494 
studies.  In particular, when a known (or unknown) confounding influence is not correctly 495 
controlled for, spurious associations can be reported.  Moreover, while studies often focus 496 
attention on the statistical significance of the associations that they detect, attention should be 497 
paid to effect sizes. Here, in a broad sense, effect size could be understood to imply: the 498 
magnitude of the increase or decrease in mutation rates, or the target size (the number of 499 
nucleotides in the genome affected), or the number of mutational processes for which this 500 
pattern is relevant. Patterns which are subtle in magnitude (e.g. reduced mutation rates at 501 
accessible chromatin), which affect narrow regions of the genome (e.g. CTCF/cohesin bound 502 
sites), or which occur only under rarely occurring mutational regimes (e.g. hypermutation due to 503 
UV damage at TF binding sites) can be important because they provide insight into DNA repair 504 
and other molecular mechanisms. However, the impact of these biases on cells can be 505 
relatively small compared to other mechanisms.  In contrast, the domain-scale mutation rate 506 
variability associated with replication time affects the entire genome, has large differences in 507 
rates between peaks and valleys, and is evident for many individual mutational processes.  508 





A final note of caution concerns making analogies between mutation rate variation in somatic 510 
cells and the germline – the latter are, of course, also of high interest because they shape the 511 
genetic variability of populations, drive evolution, and impact the occurrence of genetic 512 
diseases. Mutation patterns have been examined in the human germline by analysis of 513 
population diversity [68,69,105], de novo mutations gleaned from sequencing parent-offspring 514 
trios [106,107] and also the evolutionary divergence between primates [17,18,59,108]. While 515 
indeed certain trends are, at first instance, similar to those observed in somatic cells, there are 516 
also substantial differences in mutation rate variability between the human germline and soma, 517 
including an overall reduced association of mutations with replication timing at the megabase 518 
scale [18,21,109]. These differences and the mechanisms underlying them are an important 519 
direction for future work. 520 
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